옵션 체인은 다양한 행사가격과 만기일에 대한 ImmuCell의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 ImmuCell에 대한 시장 심리를 평가합니다..

ImmuCell (NASDAQ:ICCC) 주식, 옵션 체인

ImmuCell

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ICCC

KRUS

MANU

PSMT

수요일 오전(미 동부 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:

수요일 주목해야 할 주식: 맨체스터 유나이티드, 프라이스스마트, 쿠라 스시 그리고 2종목

ImmuCell Corp

ImmuCell Corporation (Nasdaq:&nbsp;ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;announced that it has settled an insurance claim covering some of the losses incurred from production contamination events.
The Company settled a long outstanding insurance claim related to previously disclosed contamination events in its production process incurred from late 2022 through April of 2024. The Company has accepted a settlement in the amount of $426,587, which is in addition to the $250,000 that was paid on this claim and recognized for financial statement purposes during the third quarter of 2023.

Legal

ImmuCell Settles Insurance Claim For $426K Covering Production Contamination Losses, Adding To $250K Paid In Q3 2023

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5">Preliminary, Unaudited Total Sales Results: &nbsp;</td>
</tr>
<tr>
<td>2024</td>
<td>2023</td>
<td>$ Increase</td>
<td colspan="1">% Increase</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>During the Three-Month Periods Ended December 31,</td>
<td>$7.8 million</td>
<td>$5.1 million</td>
<td>$2.7 million</td>
<td>52%</td>
</tr>
<tr>
<td>During the Years Ended December 31,</td>
<td>$26.5 million</td>
<td>$17.5 million</td>
<td>$9.0 million</td>
<td>52%</td>
</tr>
</tbody>
</table>
</figure>
 During the three-month period ended December 31, 2024, annualized production output was approximately 103% of the Company's estimated full capacity of approximately $30 million per year. This production output helped reduce the backlog of orders to approximately $4.4 million as of January 1, 2025 from approximately $9.4 million as of January 1, 2024. The Company believes that the current backlog reflects strong demand as distributors work to replenish their buffer stocks and as end-users place orders in advance of peak calving season during the first quarter.

Reported Earlier, ImmuCell Preliminary Q4 Sales Of $7.8M (+52% YoY) and Fiscal 2024 Of $26.5M (+52% YoY), Driven by Increased Production

ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) reported quarterly losses of $(0.09) per share. This is a 25 percent increase over losses of $(0.12) per share from the same period last year. The company reported $6.01 million in sales this quarter. This is a 11.40 percent increase over sales of $5.40 million the same period last year.

ImmuCell Q3 GAAP EPS $(0.09) Up From $(0.12) YoY, Sales $6.01M Up From $5.40M YoY

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

ImmuCell Corporation (Nasdaq:&nbsp;ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="6">Preliminary, Unaudited Total Sales Results: &nbsp;</td>
</tr>
<tr>
<td>2024</td>
<td>2023</td>
<td colspan="2">$ Increase</td>
<td colspan="1">% Increase</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>During the Three-Month Periods Ended September 30,</td>
<td>$6.0 million</td>
<td>$5.4 million</td>
<td colspan="2">$615,000</td>
<td>11%</td>
</tr>
<tr>
<td>During the Nine-Month Periods Ended September 30,</td>
<td>$18.7 million</td>
<td>$12.4 million</td>
<td colspan="2">$6.4 million</td>
<td>51%</td>
</tr>
<tr>
<td>During the Twelve-Month Periods Ended September 30,</td>
<td>$23.8 million</td>
<td>$16.3 million</td>
<td colspan="2">$7.6 million</td>
<td>46%</td>
</tr>
</tbody>
</table>
</figure>
 During the three-, nine- and twelve-month periods ended September 30, 2024, annualized production output was approximately 73%, 81% and 77%, respectively, of the Company's estimated full capacity of approximately $30 million per year.
As of September 30, 2024, the backlog of orders aggregated approximately $7.3 million. The Company believes that the current backlog reflects strong demand as distributors work to replenish their buffer stocks and as end-users place orders in advance of the first quarter calving season.
Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to continue providing this prompt, preliminary report on product sales until further notice going forward.

Guidance

ImmuCell Announces Preliminary Q3 Revenue Of $6M Up From $5.4M YoY

ImmuCell Sees Q2 $(0.20) Down From $(0.18) YoY; Product Sales $5.473M Up From $3.533M YoY

With U.S. stock futures trading mixed this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Manchester United Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) to report a quarterly loss at 27 cents per share on revenue of $162.92 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Manchester United shares gained 1.6% to $16.19 in the after-hours trading session.</li>
<li>Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) posted downbeat results for its third quarter on Tuesday. Kura Sushi shares fell 4.2% to $56.00 in the after-hours trading session.</li>
<li>Analysts are expecting PriceSmart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSMT#NASDAQ">PSMT</a>) to post quarterly earnings at $1.01 per share on revenue of $1.21 billion. The company will release earnings after the markets close. PriceSmart shares gained 1% to $79.00 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a> 
<ul>
<li>ImmuCell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) reported preliminary sales results for the second quarter. The company said it sees preliminary sales of $5.47 million up from $3.53 million in the year-ago period. ImmuCell shares climbed 8.9% to $4.67 in the after-hours trading session.</li>
<li>Analysts expect AZZ Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) to post quarterly earnings at $1.30 per share on revenue of $402.05 million. AZZ shares gained 2.7% to $77.00 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39690602/delta-air-lines-likely-to-report-lower-q2-earnings-here-are-the-recent-forecast-changes-from-wall-s">Delta Air Lines Likely To Report Lower Q2 Earnings; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo courtesy: PriceSmart

PriceSmart, Kura Sushi And 3 Stocks To Watch Heading Into Wednesday

WIIM

ImmuCell shares are trading higher after the company reported preliminary Q2 sales results.

ImmuCell Sees Prelim. Q2 Sales $5.47M Up From $3.53M YoY

ImmuCell Corporation (Nasdaq:&nbsp;ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;provided a regulatory update on the status of its product development initiative for Re-Tain&#xAE;.

Biotech

General

ImmuCell Updates Regulatory Status Of Product Development Initiative For Re-Tain

ImmuCell Reports $7.3M In Product Sales For Quarter Ended March 31, 2024

ImmuCell Anticipates No Change To Preliminary Sales Results For Q1 Ended March 31, 2024 That Were Disclosed On April 9

<h3>Gainers</h3>
<ul>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. </li>
<li>aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFE#NASDAQ">LIFE</a>) shares rose 10.45% to $1.9. The company's market cap stands at $128.7 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares increased by 7.36% to $1.75. The market value of their outstanding shares is at $85.8 million. </li>
<li>ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) shares increased by 7.27% to $5.6. The market value of their outstanding shares is at $43.4 million. </li>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares moved upwards by 6.46% to $0.16. The company's market cap stands at $6.9 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 5.34% to $1.38. The company's market cap stands at $47.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) shares declined by 6.1% to $1.38 during Tuesday's after-market session. The company's market cap stands at $47.8 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares decreased by 6.11% to $1.23. The market value of their outstanding shares is at $27.5 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares decreased by 5.95% to $1.74. The market value of their outstanding shares is at $11.4 million. </li>
<li>Medigus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGS#NASDAQ">MDGS</a>) stock declined by 5.62% to $2.52. The company's market cap stands at $4.7 million. </li>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) shares declined by 5.18% to $0.5. The market value of their outstanding shares is at $8.9 million. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock fell 4.98% to $13.76. The company's market cap stands at $14.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APYX

ATXI

AVTX

CRVS

LIFE

MDGS

MTEM

NKGN

NVOS

12 Health Care Stocks Moving In Tuesday's After-Market Session

Total sales during the twelve-month period ended March 31, 2024 were&nbsp;33%&nbsp;more than the twelve-month period ended March 31, 2023.

ImmuCell Reports Preliminary, Unaudited Sales Results For Q1 2024 Of $7.3M, Up 111% Y/Y

ImmuCell Q4 2023 EPS $(0.15) Up From $(0.22) YoY; Product Sales $5.1M Up From $3.9M YoY

ACAD

ACHC

AESI

AHCO

AIRS

ALEC

ALHC

AMBA

AMBC

APLS

ARKO

ARQT

ARRY

ATEC

AXON

BCSF

BECN

BGFV

BMBL

BWXT

BYND

CAVA

CBRL

CIVI

CLDT

CLNE

CLVT

CMLS

COMP

CPNG

CRDO

CYTK

EBAY

EHTH

ESPR

FARO

FLYW

FOUR

FSLR

GDOT

GLPI

GMRE

GSX Techedu Inc. American Depositary Shares

GOTU

GPOR

HRZN

HSIC

HURN

ICFI

ICUI

IMAX

IMXI

INGN

INSE

IPAR

JAMF

KIND

KURA

KVYO

LAZR

LGND

LGVN

Earnings Scheduled For February 27, 2024

ImmuCell Sees Prelim. Q4 Sales $5.1M, 2023 Sales $17.5M

ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) reported quarterly losses of $(0.12) per share. This is a 50 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $5.40 million in sales this quarter. This is a 12.53 percent increase over sales of $4.80 million the same period last year.

ImmuCell Q3 2023 Gaap EPS $(0.12) Down From $(0.08) YoY, Sales $5.40M Up From $4.80M YoY

AACG

ABOS

Earnings Scheduled For November 13, 2023

Comments

ImmuCell

ImmuCell (ICCC) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌